Caribou Biosciences, Inc. (NASDAQ:CRBU) Given Average Recommendation of “Buy” by Brokerages

Caribou Biosciences, Inc. (NASDAQ:CRBUGet Rating) has been given an average rating of “Buy” by the nine ratings firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $29.71.

CRBU has been the subject of a number of recent analyst reports. Brookline Capital Acquisition initiated coverage on Caribou Biosciences in a research report on Monday, February 14th. They set a “buy” rating and a $19.00 price target for the company. Citigroup upped their price target on Caribou Biosciences from $29.00 to $39.00 in a research report on Thursday, May 12th. Royal Bank of Canada began coverage on Caribou Biosciences in a research report on Thursday, February 17th. They issued an “outperform” rating and a $22.00 target price for the company. SVB Leerink increased their target price on Caribou Biosciences from $30.00 to $34.00 in a research report on Thursday, May 12th. Finally, Brookline Capital Management reissued a “buy” rating on shares of Caribou Biosciences in a research report on Monday, February 14th.

CRBU traded down $0.40 during midday trading on Tuesday, reaching $7.91. 12,889 shares of the company’s stock traded hands, compared to its average volume of 642,224. The firm has a fifty day moving average of $8.48 and a two-hundred day moving average of $11.99. The stock has a market capitalization of $480.18 million and a price-to-earnings ratio of -3.22. Caribou Biosciences has a 52 week low of $6.41 and a 52 week high of $32.65.

Caribou Biosciences (NASDAQ:CRBUGet Rating) last released its quarterly earnings results on Monday, May 9th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.03. Caribou Biosciences had a negative return on equity of 27.80% and a negative net margin of 682.39%. As a group, equities analysts predict that Caribou Biosciences will post -1.54 earnings per share for the current fiscal year.

A number of hedge funds have recently bought and sold shares of the stock. The Manufacturers Life Insurance Company increased its position in Caribou Biosciences by 12.0% during the 4th quarter. The Manufacturers Life Insurance Company now owns 10,912 shares of the company’s stock valued at $165,000 after buying an additional 1,165 shares in the last quarter. Deutsche Bank AG boosted its stake in Caribou Biosciences by 11.1% during the 4th quarter. Deutsche Bank AG now owns 13,014 shares of the company’s stock valued at $196,000 after purchasing an additional 1,296 shares during the last quarter. Squarepoint Ops LLC boosted its stake in Caribou Biosciences by 2.3% during the 4th quarter. Squarepoint Ops LLC now owns 76,691 shares of the company’s stock valued at $1,157,000 after purchasing an additional 1,691 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its stake in Caribou Biosciences by 12.4% during the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 15,652 shares of the company’s stock valued at $144,000 after purchasing an additional 1,730 shares during the last quarter. Finally, Rhumbline Advisers boosted its stake in Caribou Biosciences by 12.1% during the 4th quarter. Rhumbline Advisers now owns 19,725 shares of the company’s stock valued at $298,000 after purchasing an additional 2,126 shares during the last quarter. 62.86% of the stock is owned by institutional investors.

Caribou Biosciences Company Profile (Get Rating)

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma.

Recommended Stories

Analyst Recommendations for Caribou Biosciences (NASDAQ:CRBU)

Receive News & Ratings for Caribou Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caribou Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.